SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
72
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Maxar Technologies Inc. of Class Action Lawsuit and Upcoming Deadline – MAXR  

NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Maxar Technologies Inc. (“Maxar” or the “Company”) (NYSE:  MAXR) and certain of its officers.   The class action, filed in United States District Court, District of Colorado, and docketed under 19-cv-00124, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Maxar securities between March 29, 2018 through January 7, 2019, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Maxar securities between March 29, 2018, and January 7, 2019, both dates inclusive, you have until March 15, 2019, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

Maxar is a leading global provider of advanced space technology solutions for commercial and government markets including satellites, Earth imagery, geospatial data, and analytics, at the nexus of the new space economy, developing and sustaining its infrastructure and delivering the products, services, systems, and solutions. 

Among the Company’s assets is the WorldView-4 satellite (“WorldView-4”).  Launched in November 2016, WorldView-4 generated revenues of approximately $85 million in fiscal year 2018.  The satellite had a net book value of approximately $155 million, including related assets, as of December 31, 2018. WorldView-4 is equipped with control moment gyros (“CMGs”), which are attitude control devices generally used in spacecraft attitude control systems. 

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (ii) Maxar’s highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (iii) as a result, Maxar’s public statements were materially false and misleading at all relevant times.

On August 7, 2018, Spruce Point Capital Management (“Spruce Point”) published a research report regarding Maxar.  The Spruce Point report alleged, in part, that Maxar “has pulled one of the most aggressive accounting schemes Spruce Point has ever seen to inflate Non-IFRS earnings by 79%”.  Specifically, the report asserted that Maxar had used its acquisition of DigitalGlobe “to inflate [its] intangible assets” and had “amended its post-retirement benefit plan to book one-time gains” in a manner that “was not fully disclosed across its investor communications.”

Following publication of the Spruce Point report, Maxar’s stock price fell $5.97 per share, or 13.44%, to close at $38.44 on August 7, 2018.

Then, on January 7, 2019, Maxar disclosed that WorldView-4 had experienced a failure in its CMGs, preventing the satellite from collecting imagery due to the loss of an axis of stability.  It was further disclosed that WorldView-4 will likely not be recoverable and will no longer produce usable imagery.

Following this announcement, the Company’s stock price fell $5.69 per share, or 48.5%, over the following two trading sessions, to close at $6.03 per share on January 8, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FiEE Rockets to Profitability with 382% Revenue Surge

Updated Category News Views 170

Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...

Continue Reading
Interactive Donor Recognition: Beyond GivingTuesday

Updated Category News Views 98

Crafting Stories That Endure You ever notice how some things just fade away after the holidays? Schools don't want their donor stories to go out like last year's tinsel. Rocket Alumni Solutions strikes right at the core of this concern. They recommend crafting donor recognition that lasts beyond GivingTuesday, by anchoring the story in the school's community. This isn't...

Continue Reading
Health Net Invests $3 Million in Stockton Housing

Updated Category News Views 145

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 24

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 87

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
Biointron's RushDATA™: Speeding Up Antibody Discovery

Updated Category News Views 227

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 32

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Cardinal Infrastructure Faces Legal Scrutiny Amid Losses

Updated Category News Views 100

Cardinal Infrastructure Group Under Intense Investor Scrutiny Well, ain't this a messy soup of financial blunders? Cardinal Infrastructure Group (Nasdaq: CDNL) finds itself on the sharp end of a potential securities law investigation, thanks to some colossal screw-ups in managing project costs and estimates. Investors are rightly pissed after the company's shares...

Continue Reading
KeyCorp Plans Redemption of Series E Preferred Stock

Updated Category News Views 112

KeyCorp Drops a Major Redemption Bombshell Out of the blue, KeyCorp (NYSE: KEY) just tossed a curveball at investors with the announcement they’re redeeming every last one of their Series E Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock shares come December 15, 2026. This move is bound to stir the pot a bit even if you’ve been around the block a few...

Continue Reading
PenFed Fuels Aggie Spirit with Blackout Game Activation

Updated Category News Views 156

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Act in Crocs Class Action Suit - Deadline March 2025

Updated Category News Views 156

Investors Targeting Crocs Encouraged to Join Class Action Faruqi & Faruqi, LLP, a prominent name in securities litigation, is reaching out to investors who have experienced significant losses in Crocs stock to participate in an emerging federal class action lawsuit. The firm is particularly concerned with those who incurred losses exceeding $50,000. The deadline to assume...

Continue Reading
Chaoyang District: Fusion of Culture and Business

Updated Category News Views 57

Chaoyang: A Tapestry of Global Life Taking a stroll through Beijing's Chaoyang district, you'd catch more than just a glimpse of its soaring skyscrapers or riverside parks—you're stepping into a melting pot of cultures and modern business ethos. It’s not puffery when they say this district marries the world’s diversified cultures with dynamic business environments;...

Continue Reading
Foot Locker Poised for Earnings Growth with Nike Alliance

Updated Category News Views 251

Foot Locker on the Path to Recovery Recent analysis by Needham's analyst Tom Nikic illustrates a promising outlook for Foot Locker, Inc. (NYSE: FL), highlighting how the company is positioned for earnings recovery in the coming year. The strengthened partnership with Nike, along with growth in non-Nike brands, and recent investments in selling, general and administrative...

Continue Reading
Future Growth of Milking Automation Market to $3.68 Billion

Updated Category News Views 133

The Rising Trend of Milking Automation Market The milking automation market is currently experiencing a significant transformation, with estimates projecting a growth to USD 3.68 billion by 2030. This steady rise reflects a robust CAGR of 7.1% from an initial valuation of USD 2.61 billion. Factors driving this expansion include increasing demand for milk, labor shortages...

Continue Reading
Immatics Shares New Phase 1b Data for Melanoma Therapy IMA203

Updated Category News Views 110

Immatics Updates on ACTengine® IMA203 for Melanoma Patients Overview: Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in the development of T cell-redirecting immunotherapies, has recently announced significant advancements in its clinical trial of ACTengine® IMA203. The focus of this update is on the therapy's application in...

Continue Reading